United Therapeutics Corporation $UTHR Stock Acquired by Machina Capital S.A.S.

Machina Capital S.A.S. grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 288.1% during the third quarter, HoldingsChannel reports. The fund owned 3,524 shares of the biotechnology company’s stock after acquiring an additional 2,616 shares during the quarter. Machina Capital S.A.S.’s holdings in United Therapeutics were worth $1,910,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Illinois Municipal Retirement Fund grew its stake in United Therapeutics by 2.5% in the third quarter. Illinois Municipal Retirement Fund now owns 40,014 shares of the biotechnology company’s stock valued at $21,683,000 after purchasing an additional 972 shares during the last quarter. New York Life Investment Management LLC raised its holdings in United Therapeutics by 7.0% in the third quarter. New York Life Investment Management LLC now owns 1,106 shares of the biotechnology company’s stock worth $599,000 after purchasing an additional 72 shares in the last quarter. Gen Wealth Partners Inc purchased a new stake in shares of United Therapeutics during the third quarter valued at about $34,000. Gryphon Financial Partners LLC lifted its position in shares of United Therapeutics by 3.7% during the third quarter. Gryphon Financial Partners LLC now owns 1,650 shares of the biotechnology company’s stock valued at $894,000 after buying an additional 59 shares during the last quarter. Finally, Leuthold Group LLC lifted its position in shares of United Therapeutics by 9.3% during the third quarter. Leuthold Group LLC now owns 11,132 shares of the biotechnology company’s stock valued at $6,032,000 after buying an additional 948 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In related news, Director Christopher Patusky sold 1,210 shares of United Therapeutics stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $580.00, for a total value of $701,800.00. Following the completion of the sale, the director directly owned 2,140 shares in the company, valued at $1,241,200. This trade represents a 36.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $593.99, for a total transaction of $5,642,905.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $192,715,897.57. This trade represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 412,238 shares of company stock worth $220,975,006. Insiders own 8.60% of the company’s stock.

Latest United Therapeutics News

Here’s some of the latest news about UTHR:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target. Its forecasts point to rising EPS, from $27.46 in FY2026 to $53.67 in FY2030, suggesting expectations for substantial longer-term earnings growth. HC Wainwright coverage article
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.64 million, reducing her direct stake by 2.84%; she still owns about 324,443 shares. Director Christopher Patusky also sold 1,210 shares for $701,800, a 36.12% reduction in his position. Insider selling can create a near-term sentiment overhang, although it does not by itself indicate a change in the company’s outlook. CEO sale report Director sale report

United Therapeutics Price Performance

Shares of UTHR stock opened at $593.31 on Friday. The stock’s fifty day moving average price is $540.58 and its 200 day moving average price is $535.80. United Therapeutics Corporation has a 1-year low of $455.63 and a 1-year high of $614.23. The company has a market cap of $25.27 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 3.99 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The business had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the business posted $7.16 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.90 earnings per share for the current year.

United Therapeutics announced that its board has approved a stock buyback program on Thursday, October 22nd that authorizes the company to repurchase $2 billion in shares. This buyback authorization authorizes the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a report on Monday, October 26th. The Goldman Sachs Group reiterated a “sell” rating and set a $368.00 price objective on shares of United Therapeutics in a research note on Thursday, October 15th. HC Wainwright initiated coverage on shares of United Therapeutics in a research report on Monday. They set a “buy” rating and a $660.00 target price for the company. Morgan Stanley raised their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Finally, JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $676.40.

United Therapeutics Company Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.